The Latest Press Releases
Item 8.01. Other Events As previously disclosed, on December 30, 2021, Greenlane Holdings, Inc. (the “Company”) entered into a Secured Promissory Note (the “Note”) with Aaron LoCascio, the former President and co-founder of the Company and a member of the Company’s Board of Directors, which provides for a loan of $8.0 million maturing on June…
Read More “8-K Other Events – Greenlane Holdings, Inc. (0001743745) June 30” »
Item 7.01 Regulation FD Disclosure. On July 1, 2022, Intercept Pharmaceuticals, Inc. (“Intercept”) issued a press release announcing the closing of its previously announced transaction with Advanz Pharma. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference. Intercept will follow with a further Current Report on Form 8-K containing…
Read More “8-K Reg FD – INTERCEPT PHARMACEUTICALS, INC. (0001270073) July 01” »
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain OfficersOn May 17, 2022, the Compensation Committee of Brinker International, Inc. (the “Company”) recommended, and on June 30, 2022, the Board of Directors of the Company approved, a cash retention bonus for Steve Provost, Executive Vice…
Read More “8-K Emp Changes – BRINKER INTERNATIONAL, INC (0000703351) June 30” »
Item 1.01 Entry Into Material Definitive Agreement On July 1, 2022, Palantir Technologies Inc. (the “Company”) and its subsidiary Palantir USG, Inc. (the “Guarantor”) entered into Amendment No. 13 to Revolving Credit Agreement and Incremental Agreement, dated as of July 1, 2022 (the “Thirteenth Amendment”), among the Company, the Guarantor, the lenders party thereto, and…
Read More “8-K Material Agrmt – Palantir Technologies Inc. (0001321655) July 01” »
Item 3.02. Unregistered Sales of Equity Securities.On July 1, 2022, AllianceBernstein Holding L.P. (“AB Holding”) and AllianceBernstein L.P. (“AB” and together with AB Holding, the “AB Parties”) completed their previously announced acquisition of 100% of the equity interests of CarVal Investors, L.P. (the “Acquisition”) held by West End Management, L.P. (f/k/a CarVal Investors Management L.P.)…
Read More “8-K Other Events – ALLIANCEBERNSTEIN HOLDING L.P. (0000825313) July 01” »
Item 1.01 Entry into a Material Definitive Agreement. On June 30, 2022, Ares Capital Corporation (the “Registrant”) and Ares Capital CP Funding LLC, an indirect wholly owned subsidiary of the Registrant (“Ares Capital CP”), entered into an amendment (the “CP Amendment”) to the documents governing Ares Capital CP’s revolving funding facility (the “CP Funding Facility”)…
Read More “8-K Other Events Material Agrmt – ARES CAPITAL CORP (0001287750) June 30” »
Item 5.07. Submission of Matters of a Vote of Security HoldersThe Annual Meeting of Stockholders was held on June 30, 2022. A total of 17,774,259.82 shares were voted in person or by proxy, representing 76.06% of the shares entitled to be voted. The following are the final voting results on proposals considered and voted upon…
Read More “8-K Vote – Creative Media & Community Trust Corp (0000908311) June 30” »
Item 3.01.Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.As previously disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on January 4, 2022, on December 31, 2021, Conformis, Inc. (the “Company”) received a notification letter from the Listing Qualifications Staff…
Read More “8-K Delisting – Conformis Inc (0001305773) June 30” »
Item 1.01Entry into a Material Definitive Agreement. Securities Purchase AgreementOn June 30, 2022, X4 Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with several institutional accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a private placement (the “Private Placement”)…
Read More “8-K Other Events Material Agrmt – X4 Pharmaceuticals, Inc (0001501697) June 30” »
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 1, 2022, Endo International plc (the “Company”) received notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, because the closing bid price for the Company’s common stock has fallen below…
Read More “8-K Delisting – Endo International plc (0001593034) July 01” »